Company profile: Tiziana Life Sciences
1.1 - Company Overview
Company description
- Provider of biotechnology therapies focused on discovery and development of novel molecules in oncology and immunology, including Intranasal Foralumab (anti-CD3 nasal immunotherapy for neuroinflammatory and neurodegenerative diseases), Anti IL-6R mAb (TZLS-501) to reduce inflammation in idiopathic pulmonary fibrosis and autoimmune diseases, and Milciclib, a CDK-targeting cancer therapy.
Products and services
- Milciclib: A small-molecule inhibitor that blocks cyclin-dependent kinases and other kinases to control cancer cell growth and progression, used in cancer treatment
- Intranasal Foralumab: A fully human anti-CD3 monoclonal antibody nasal immunotherapy that reduces microglial activation and promotes anti-inflammatory responses to treat neuroinflammatory and neurodegenerative diseases
- Anti IL-6R mAb (TZLS-501): A fully human monoclonal antibody that targets IL-6 receptors to reduce inflammation, with potential use in idiopathic pulmonary fibrosis and autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tiziana Life Sciences
ADC Therapeutics
HQ: Switzerland
Website
- Description: Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Therapeutics company profile →
T-knife Therapeutics
HQ: Germany
Website
- Description: Provider of T cell receptor-based therapies for cancer, using a humanized TCR mice platform carrying human TCRαβ gene loci to recombine a broad repertoire of human TCRs, enabling efficient generation and virtual selection of receptors targeting human tumor antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T-knife Therapeutics company profile →
Tmunity Therapeutics
HQ: United States
Website
- Description: Provider of engineered T cell therapies and platforms, developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms to unleash the immunological potential of T cells, treat a wide range of disease indications, and enable control over T cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tmunity Therapeutics company profile →
Visterra
HQ: United States
Website
- Description: Provider of therapeutic and diagnostic products and R&D for infectious diseases, leveraging structure-based design informed by glycobiology and glycochemistry. Pipeline includes Sibeprenlimab (VIS649) for IgA nephropathy, VIS171 (modified IL-2) to activate Tregs, and VIS513 for dengue. Platforms: HIEROTOPE for epitope selection/design and ViSTAR Fc modifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visterra company profile →
MacroGenics
HQ: United States
Website
- Description: Provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MacroGenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tiziana Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tiziana Life Sciences
2.2 - Growth funds investing in similar companies to Tiziana Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tiziana Life Sciences
4.2 - Public trading comparable groups for Tiziana Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →